Pharming posts positive Phase II topline data for leniolisib in immune dysregulation
Pharming Group NV has reported positive topline Phase II data for its drug leniolisib, used to treat primary immunodeficiencies with immune dysregulation. The study indicated that the drug was generally well-tolerated and showed broad clinical improvement, including reduced lymphoproliferation. Results are yet to be pr